Compare FUSE & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FUSE | CMMB |
|---|---|---|
| Founded | 2013 | 2004 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 10.9M |
| IPO Year | 2025 | 2023 |
| Metric | FUSE | CMMB |
|---|---|---|
| Price | $0.28 | $1.22 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 61.9K | 59.0K |
| Earning Date | 11-03-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 96.38 | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $7,714,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $28.00 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.22 | $0.92 |
| 52 Week High | $3.67 | $2.99 |
| Indicator | FUSE | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 35.08 | 43.53 |
| Support Level | $0.22 | $0.99 |
| Resistance Level | $0.41 | $1.91 |
| Average True Range (ATR) | 0.05 | 0.19 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 21.73 | 20.74 |
Fusemachines Inc is a provider of enterprise AI solutions, offering products such as AI Studio, AI Engines, and AI Agents, along with supporting services across various industries. Its solutions are supported by a talent pool from underserved communities, enabling scalable and high-quality AI delivery while promoting access to AI. The Company serves clients across industries, including healthcare, media, technology, and government, helping address challenges such as improving forecasting accuracy, reducing data entry errors, automating recruitment, and detecting fraud. Its product suite includes AI Studio, AI Engines, and AI Agents, designed to build, deploy, and scale AI solutions, and it operates in Nepal and the United States.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.